The Washington Post reports on uncertainties facing gene-edited livestock endeavors.
The company, which had raised $55.5 million in February, said its investors have agreed to contribute an additional $30 million.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
A systematic analysis of CRISPR genome editing at nearly 1,500 target sites has yielded some patterns that could make genome editing more precise.
The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.
The pharma and biotech company said it plans to use the genome editing technology in its bioproduction products and services and in stem cells for research.
The method, called negative enrichment, protects DNA regions of interest prior to degrading the surrounding DNA, making the target fragments easier to read.
In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.
Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.
As they dig into the data on He Jiankui's genome editing experiment, CRISPR researchers say the work he did raises many scientific questions.
A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.
The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.
University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.
In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.